Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H, Matsuno Y, Kusumoto-Matsuo R, Kojima S, Ueno T, Ikegami M, Kitada R, Sumiyoshi-Okuma H, Kojima Y, Yonemori K, Yatabe Y, Takamochi K, Suzuki K, Yoshioka KI, Mano H, Kohsaka S. Ikeuchi H, et al. Among authors: kojima s, kojima y. Oncogene. 2024 Oct;43(41):3037-3048. doi: 10.1038/s41388-024-03105-1. Epub 2024 Aug 3. Oncogene. 2024. PMID: 39095584
BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, Kojima Y, Yonemori K, Fujiwara Y, Kinoshita T, Ushijima T, Tamura K. Kawachi A, et al. Among authors: kojima y. Breast Cancer Res Treat. 2020 Jun;181(2):323-329. doi: 10.1007/s10549-020-05647-w. Epub 2020 Apr 20. Breast Cancer Res Treat. 2020. PMID: 32314111 Clinical Trial.
HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix.
Mizuno T, Kojima Y, Yonemori K, Yoshida H, Sugiura Y, Ohtake Y, Okuma HS, Nishikawa T, Tanioka M, Sudo K, Shimomura A, Noguchi E, Kato T, Shimoi T, Uno M, Ishikawa M, Fujiwara Y, Ohe Y, Tamura K. Mizuno T, et al. Among authors: kojima y. Oncol Lett. 2020 Oct;20(4):38. doi: 10.3892/ol.2020.11899. Epub 2020 Jul 23. Oncol Lett. 2020. PMID: 32802162 Free PMC article.
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer.
Mizuno T, Kojima Y, Yonemori K, Yoshida H, Sugiura Y, Ohtake Y, Okuma HS, Nishikawa T, Tanioka M, Sudo K, Shimomura A, Noguchi E, Kato T, Shimoi T, Uno M, Ishikawa M, Fujiwara Y, Ohe Y, Tamura K. Mizuno T, et al. Among authors: kojima y. Oncol Lett. 2020 Dec;20(6):336. doi: 10.3892/ol.2020.12200. Epub 2020 Oct 7. Oncol Lett. 2020. PMID: 33123247 Free PMC article.
Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
Hasegawa N, Kohsaka S, Kurokawa K, Shinno Y, Takeda Nakamura I, Ueno T, Kojima S, Kawazu M, Suehara Y, Ishijima M, Goto Y, Kojima Y, Yonemori K, Hayashi T, Saito T, Shukuya T, Takahashi F, Takahashi K, Mano H. Hasegawa N, et al. Among authors: kojima s, kojima y. Cancer Sci. 2021 Oct;112(10):4393-4403. doi: 10.1111/cas.15084. Epub 2021 Aug 18. Cancer Sci. 2021. PMID: 34310819 Free PMC article.
Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
Uchihara M, Tanioka M, Kojima Y, Nishikawa T, Sudo K, Shimoi T, Noguchi E, Maeshima AM, Yonemori K. Uchihara M, et al. Among authors: kojima y. Int J Clin Oncol. 2021 Dec;26(12):2275-2281. doi: 10.1007/s10147-021-02021-8. Epub 2021 Sep 1. Int J Clin Oncol. 2021. PMID: 34468885 Clinical Trial.
2,241 results